Literature DB >> 11095611

RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection.

H Levkovitch-Verbin1, C Harris-Cerruti, Y Groner, L A Wheeler, M Schwartz, E Yoles.   

Abstract

PURPOSE: To establish a method for morphometric analysis of retrogradely labeled retinal ganglion cells (RGCs) of the mouse retina, to be used for the study of molecular aspects of RGC survival and neuroprotection in this model; to evaluate the effect of overexpression of Cu-Zn-superoxide dismutase (CuZnSOD) on RGC survival after severe crush injury to the optic nerve, and to assess the effect of the alpha2-adrenoreceptor agonist brimonidine, recently shown to be neuroprotective, on RGC survival.
METHODS: A severe crush injury was inflicted unilaterally in the orbital portion of the optic nerves of wild-type and transgenic (Tg-SOD) mice expressing three to four times more human CuZnSOD than the wild type. In each mouse all RGCs were labeled 72 hours before crush injury by stereotactic injection of the neurotracer dye FluoroGold (Fluorochrome, Denver, CO) into the superior colliculus. Survival of RGCs was then assessed morphometrically, with and without systemic injection of brimonidine.
RESULTS: Two weeks after crush injury, the number of surviving RGCs was significantly lower in the Tg-SOD mice (596.6 +/- 71.9 cells/mm(2)) than in the wild-type control mice (863. 5 +/- 68 cells/mm(2)). There was no difference between the numbers of surviving RGCs in the uninjured retinas of the two strains (3708 +/- 231.3 cells/mm(2) and 3904 +/- 120 cells/mm(2), respectively). Systemic injections of brimonidine significantly reduced cell death in the Tg-SOD mice, but not in the wild type.
CONCLUSIONS: Overexpression of CuZnSOD accelerates RGC death after optic nerve injury in mice. Activation of the alpha2-adrenoreceptor pathway by brimonidine enhances survival of RGCs in an in vivo transgenic model of excessive oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095611

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  63 in total

1.  Dose-dependent treatment of optic nerve crush by exogenous systemic mutant erythropoietin.

Authors:  Timothy A Sullivan; Eldon E Geisert; Justin P Templeton; Tonia S Rex
Journal:  Exp Eye Res       Date:  2012-01-27       Impact factor: 3.467

2.  Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial.

Authors:  Barbara Wilhelm; Holger Lüdtke; Helmut Wilhelm
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-09-08       Impact factor: 3.117

3.  Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization.

Authors:  Joseph R Ferencz; Gila Gilady; Orly Harel; Michael Belkin; Ehud I Assia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-03-23       Impact factor: 3.117

4.  Retinal ion regulation in a mouse model of diabetic retinopathy: natural history and the effect of Cu/Zn superoxide dismutase overexpression.

Authors:  Bruce A Berkowitz; Marius Gradianu; David Bissig; Timothy S Kern; Robin Roberts
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-12-13       Impact factor: 4.799

5.  Changes in ocular aquaporin expression following optic nerve crush.

Authors:  Adnan Dibas; Hidehiro Oku; Masayuki Fukuhara; Takuji Kurimoto; Tsunehiko Ikeda; Rajkumar V Patil; Najam A Sharif; Thomas Yorio
Journal:  Mol Vis       Date:  2010-03-03       Impact factor: 2.367

6.  Brimonidine is neuroprotective against glutamate-induced neurotoxicity, oxidative stress, and hypoxia in purified rat retinal ganglion cells.

Authors:  Kelvin Yoon Chiang Lee; Mao Nakayama; Makoto Aihara; Yi-Ning Chen; Makoto Araie
Journal:  Mol Vis       Date:  2010-02-17       Impact factor: 2.367

7.  Gene expression in the mouse eye: an online resource for genetics using 103 strains of mice.

Authors:  Eldon E Geisert; Lu Lu; Natalie E Freeman-Anderson; Justin P Templeton; Mohamed Nassr; Xusheng Wang; Weikuan Gu; Yan Jiao; Robert W Williams
Journal:  Mol Vis       Date:  2009-08-31       Impact factor: 2.367

8.  Effects of beta-adrenergic receptor antagonists on oxidative stress in purified rat retinal ganglion cells.

Authors:  Zi-Kui Yu; Yi-Ning Chen; Makoto Aihara; Wei Mao; Saiko Uchida; Makoto Araie
Journal:  Mol Vis       Date:  2007-06-11       Impact factor: 2.367

9.  Immune maintenance in glaucoma: boosting the body's own neuroprotective potential.

Authors:  Michal Schwartz; Anat London
Journal:  J Ocul Biol Dis Infor       Date:  2009-07-21

10.  Early cellular signaling responses to axonal injury.

Authors:  Thomas J Lukas; Ai Ling Wang; Ming Yuan; Arthur H Neufeld
Journal:  Cell Commun Signal       Date:  2009-03-13       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.